ID   PC3PR
AC   CVCL_B7P9
SY   PC3-PR
DR   cancercelllines; CVCL_B7P9
DR   Wikidata; Q112930288
RX   PubMed=20687223;
RX   PubMed=23876400;
RX   PubMed=27687545;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Bone; UBERON=UBERON_0002481.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0035 ! PC-3
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=20687223; DOI=10.1002/pros.21185;
RA   Kojima K., Fujita Y., Nozawa Y., Deguchi T., Ito M.;
RT   "MiR-34a attenuates paclitaxel-resistance of hormone-refractory
RT   prostate cancer PC3 cells through direct and indirect mechanisms.";
RL   Prostate 70:1501-1512(2010).
//
RX   PubMed=23876400; DOI=10.1016/j.cyto.2013.06.313;
RA   Kato T., Fujita Y., Nakane K., Mizutani K., Terazawa R., Ehara H.,
RA   Kanimoto Y., Kojima T., Nozawa Y., Deguchi T., Ito M.;
RT   "CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3
RT   prostate cancer cells by increasing secretion of MMPs 2/9 and by
RT   activating ERK and Rac signaling.";
RL   Cytokine 64:251-257(2013).
//
RX   PubMed=27687545; DOI=10.1016/j.bbrc.2016.09.128;
RA   Sobue S., Mizutani N., Aoyama Y., Kawamoto Y., Suzuki M., Nozawa Y.,
RA   Ichihara M., Murate T.;
RT   "Mechanism of paclitaxel resistance in a human prostate cancer cell
RT   line, PC3-PR, and its sensitization by cabazitaxel.";
RL   Biochem. Biophys. Res. Commun. 479:808-813(2016).
//